CD8A and neoplasm: Notably, patients with cytotoxic T‐cell infiltration within the tumor microenvironment, as well as those exhibiting elevated levels of active circulating CD8+ T cells coupled with downregulation of neutrophil‐associated markers, were found to derive significant clinical benefit from pembrolizumab treatment [56].